Follows people with Crohn's disease after an ALLO-ASC-CD cell treatment
Checks the long-term safety of ALLO-ASC-CD in adults with Crohn's disease.
Plain-language title generated from the registry record
Registry title: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
Key facts
- Where
- Seoul, South KoreaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT03183661, who can take part
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
- Severance hospitalSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anterogen Co., Ltd.
- Trial code
- NCT03183661
- Record updated
- 25 August 2023
- Original description
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.Read full original descriptionShow less
Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101)
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
Inclusion: Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101; Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion: Subjects who are considered not suitable for the study by the principal investigator.